Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lidocaine + cetylpyridinium chloride lozenge versus Mebucaine CL for sore throat pain
2010-021653-39Phase 3Completed
- Sponsor
- Novartis Consumer Health
- Start
- Sep 2010
- Modality
- Small Molecules, Conventional Liposomes → Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lidocaine and cetylpyridinium chloride in upper respiratory infection (URI) (2 arms), sponsored by Novartis Consumer Health. Started Sep 2010; status: completed.
02
Drugs
lidocainecetylpyridinium chloride
03
Conditions
upper respiratory infection (URI)
Beyond the preview
Go deeper on 2010-021653-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021653-39.